Innovative Therapeutics in Oncology and Neuroscience

29 QINLOCK A Potential Best-In-Class Treatment for Advanced GIST QINLOCK (ripretinib) 50 mg tablets mPFS ORR MOS Ripretinib (n = 85) 6.3 months (27.6 weeks) 9.4% 15.1 months Placebo (n = 44)¹ 1.0 month (4.1 weeks) p-value <0.0001 0% 6.6 months Approved 0.0504 Nominal p-value = 0.00042 Significantly reduced the risk of disease progression or death by 85% (Hazard Ratio of 0.15, p-value <0.0001) compared to placebo Current Status QINLOCK remains the standard of care and only approved therapy in patients with 4L GIST; Successful NRDL inclusion in March 2023 Core Opportunity ~30K annual incidence of GIST in China; many GIST patients on TKIs develop tumor progression due to secondary mutations Source: Deciphera corporate presentation, September 2019. Notes: TKIs tyrosine kinase inhibitors. The trademarks and registered trademarks within are the property of their respective owners. (1) One patient was randomized to placebo but did not receive study drug; (2) According to the pre- specified hierarchical testing procedure of the endpoints, the hypothesis testing of mOS cannot be formally conducted unless the test of ORR is statistically significant. Because statistical significance was not achieved for ORR, the hypothesis testing of OS was not formally performed. Clinical Data - Oncology

View entire presentation